Together, these findings imply that sulforaphane’s stable binding to TNF, characterized by minimal fluctuations and consistent interactions, enhances its therapeutic potential in mitigating neuroinflammation associated with AD. The gene discussed is TNF; the disease is Alzheimer disease.